# Dexamethasone in Reducing Everolimus-Induced Oral Stomatitis in Patients With Cancer

> **NCT03839940** · PHASE3 · TERMINATED · sponsor: **Alliance for Clinical Trials in Oncology** · enrollment: 39 (actual)

## Conditions studied

- Malignant Neoplasm

## Interventions

- **DRUG:** Dexamethasone
- **OTHER:** Placebo
- **OTHER:** Questionnaire
- **OTHER:** Quality-of-Life Assessment
- **DRUG:** Everolimus

## Key facts

- **NCT ID:** NCT03839940
- **Lead sponsor:** Alliance for Clinical Trials in Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-06-03
- **Primary completion:** 2021-01-08
- **Final completion:** 2022-08-03
- **Target enrollment:** 39 (ACTUAL)
- **Why stopped:** Severe lack of accrual
- **Last updated:** 2025-01-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03839940

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03839940, "Dexamethasone in Reducing Everolimus-Induced Oral Stomatitis in Patients With Cancer". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT03839940. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*